Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:58:27.539Z.
Calculation as of: 2026-10-06T20:58:27.539Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79d0a2820bd4cbdc8dee1371cb6304dc007cf4c401fb8f8a9623f82368031b99
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
TransCode Therapeutics, Inc.
Market Cap
$1.88M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.81M
EV/EBITDA Ratio
N/A
TTM Avg
570.22x
3Y Avg
570.22x
5Y Avg
570.22x
Market Cap
$2.13M
EV/EBITDA Ratio
N/A
TTM Avg
10388992794.84x
3Y Avg
12435877641.77x
5Y Avg
12435877641.77x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) | $1.88M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | N/A | 570.22x | 570.22x | 570.22x |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 10388992794.84x | 12435877641.77x | 12435877641.77x |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
